Developer docs
API playgroundTry for free, no card

Search company profiles

BioLytical Laboratories

Full company profile

uuid0005okv

Namestring
BioLytical Laboratories
Legal namestring
bioLytical Laboratories Inc.
Websiteurl
biolytical.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

BioLytical Laboratories Inc. is a privately held Canadian biotechnology company headquartered in Richmond, British Columbia, with a U.S. operating office in Ferndale, Washington. Founded in 2005, the company develops and manufactures rapid point-of-care diagnostic tests built around a proprietary flow-through immunoassay platform that delivers results in as little as one minute. Its product portfolio is organized under two sub-brands: INSTI (one-minute tests for HIV self-test, HIV-1/2 antibody, multiplex HIV/Syphilis, and HCV antibody) and iStatis (15-minute tests for COVID-19 antigen, syphilis antibody, and hepatitis B surface antigen).

The company derives revenue primarily through the sale of hardware diagnostic kits to a diversified mix of channel partners, including regional and international distributors, pharmacy networks, group purchasing organizations such as Vizient, and government/NGO-led public health programs including Together TakeMeHome and Coalition Plus. Pricing is not publicly disclosed and is negotiated through dedicated account managers. BioLytical has secured multi-jurisdictional regulatory approvals (FDA, Health Canada, WHO Prequalification, CE Mark, Australian ARTG) and distributes in 70+ countries, with more than 35 million people tested cumulatively using its products.

BioLytical's go-to-market combines channel-partner distribution with event-driven demand generation at major healthcare conferences (Medica, Arab Health, USCHA, IAS, EACS) and a direct-to-consumer motion for the INSTI HIV Self Test via pharmacies and U.S. public health programs. Its competitive position rests on test speed (the world's fastest HIV test), integrated control features, room-temperature stability eliminating cold chain requirements, and a regulatory footprint spanning 70+ jurisdictions.

Short descriptiontext

BioLytical Laboratories is a Canadian rapid diagnostics company that develops and manufactures one-minute INSTI and 15-minute iStatis point-of-care tests for HIV, HCV, syphilis, hepatitis B, and COVID-19, distributed in over 70 countries via channel partners, pharmacies, and public health programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRichmond, Canada
HQ citystring
Richmond
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostic tests, point-of-care testing, HIV self-testing, flow-through immunoassay, infectious disease diagnostics
Industry2 codes
PRIMARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Rapid Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Rapid Diagnostic Test Kits
TypeHardware Sales
Description

Sale of INSTI and iStatis rapid test products for HIV, HCV, Syphilis, COVID-19, and Hepatitis B. Products are sold to healthcare providers, distributors, pharmacies, and directly to consumers. Manufacturing with short lead times and fast shipping.

biolytical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1INSTI
Description

Premium rapid test brand featuring the world's fastest HIV test with results in 1 minute, includes HIV Self Test, HIV-1 HIV-2 Antibody Test, Multiplex HIV-1/2 Syphilis Test, and HCV Antibody Test.

biolytical.com
+1 more record
Core offering1 text field

BioLytical Laboratories develops and manufactures rapid point-of-care diagnostic test kits under the INSTI (1-minute tests) and iStatis (15-minute tests) brands for HIV, HCV, Syphilis, COVID-19, and Hepatitis B. The company sells both professional-use tests to healthcare providers and self-tests directly to consumers, using proprietary flow-through immunoassay technology that delivers results without timing devices, refrigeration, or specialized equipment. Products are distributed globally across 70+ countries through distributor networks, pharmacy chains, and group purchasing organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >99% sensitivity (Positive Percent Agreement) and >99% specificity (Negative Percent Agreement) for INSTI HIV tests
+3 more records
Product overview1 text field

BioLytical Laboratories offers a portfolio of rapid point-of-care diagnostic tests organized under two sub-brands: INSTI (1-minute tests) and iStatis (15-minute tests). The INSTI line includes HIV self-test, HIV-1/2 antibody test, multiplex HIV/syphilis test, and HCV antibody test. The iStatis line includes COVID-19 antigen tests (home and professional), syphilis antibody test, and hepatitis B surface antigen test. The company utilizes proprietary flow-through immunoassay technology that enables near-instant results without the need for timing devices, refrigeration, or complex procedures. Tests are designed for both self-use (consumer) and professional point-of-care settings, supporting disease screening in over 70 countries.

Product and service8 records
1INSTI HIV Self Test
CategoryHIV self-testing (consumer)
Description

A rapid, single-use, visual-read self-test that detects antibodies against HIV type 1 and type 2 using a drop of blood from a finger prick. Provides results in 60 seconds with 99.8% sensitivity and 99.5% specificity. Designed for personal at-home use by individual consumers.

2INSTI HIV-1 HIV-2 Antibody Test
CategoryHIV point-of-care testing (professional)
Description

A rapid, single-use, visual-read flow-through immunoassay for professional use that detects antibodies against HIV-1 and HIV-2 using capillary whole blood, venous whole blood, serum, or plasma samples. Delivers results in 1 minute and is used by healthcare professionals in clinical settings.

3INSTI Multiplex HIV-1/2 Syphilis Antibody Test
CategoryMultiplex infectious disease testing (professional)
Description

A rapid multiplex test that detects antibodies to both HIV-1/2 and syphilis from a single sample, providing two results in one minute. Designed for point-of-care professional use in clinical settings.

4INSTI HCV Antibody Test
CategoryHCV point-of-care testing (professional)
Description

The world's first CE-marked 1-minute hepatitis C antibody rapid test, enabling detection of HCV antibodies to help eliminate HCV as a public health problem. For professional use.

5iStatis COVID-19 Antigen Home Test
CategoryCOVID-19 antigen testing (consumer)
Description

A rapid antigen home test for detecting active COVID-19 infection, providing results in 15 minutes. Received WHO Prequalification for global market access and is designed for personal use at home.

6iStatis COVID-19 Antigen Test
CategoryCOVID-19 antigen testing (professional)
Description

A professional-use rapid antigen test for detecting active COVID-19 infection, delivering results in 15 minutes. Authorized by Health Canada for identifying active infections in clinical settings.

7iStatis Syphilis Antibody Test
CategorySyphilis point-of-care testing (professional)
Description

A rapid point-of-care test for detecting syphilis antibodies, providing results in under 15 minutes. Included in the Australian Register of Therapeutic Goods (ARTG) for distribution in Australia. For professional use.

8iStatis Hepatitis B Surface Antigen Test
CategoryHepatitis B point-of-care testing (professional)
Description

North America's first Health Canada-authorized rapid point-of-care test for hepatitis B, providing results in 15 minutes. Designed to improve access to hepatitis B screening and early diagnosis. For professional use.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-23
Description

Walgreens serves as a distribution partner for bioLytical's INSTI HIV Self Tests. bioLytical donated 4,200 INSTI HIV Self Tests for National HIV Testing Day activities at Walgreens locations across the USA, marking the company's first donation of self-tests within the US market.

2Together TakeMeHome
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to support Together TakeMeHome's national program delivering free HIV self-tests directly to individuals across the United States. bioLytical's INSTI HIV Self Test is included in this free testing initiative.

biolytical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Vizient awarded an innovative technology contract to bioLytical for the INSTI rapid HIV test. This contract enables healthcare facilities within the Vizient network to access INSTI testing products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with international NGO Coalition Plus to donate HIV tests supporting International Testing Week initiatives aimed at increasing global testing access.

5Kenya Pharmacy Networks
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

INSTI HIV Self Test launched through Kenya's regulated pharmacy network, enabling wider access to HIV self-testing across Kenya.

biolytical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active participation in WHO-UNITAID Manufacturers events to support global access to affordable diagnostic testing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OraSure is the most direct peer, selling the OraQuick HIV self-test and other rapid infectious disease diagnostics with similar point-of-care positioning, OTC approvals, and global health distribution — directly competing with INSTI on HIV self-testing.

2Abbott Diagnostics (Alere)
TypeBroad incumbent
Description

Abbott is a global diagnostics incumbent whose rapid test portfolio (BinaxNOW, Determine, m-PIMA) competes across HIV, hepatitis, and infectious disease markets with much greater scale, distribution reach, and hospital contracts than BioLytical.

TypeDirect peer
Description

Chembio develops rapid point-of-care immunoassay tests for HIV, syphilis, and febrile illness with comparable technology, regulatory pathway (FDA, WHO Prequalification), and target customer base of NGOs and public health programs.

TypeDirect peer
Description

SD Biosensor is a Korean rapid diagnostics maker with HIV, COVID, and infectious disease lateral-flow products sold globally, including strong presence in emerging markets and WHO Prequalified assays — directly competing with both INSTI and iStatis.

TypeDirect peer
Description

Trinity Biotech manufactures diagnostic tests for HIV, hepatitis, and other infectious diseases sold through clinical labs and point-of-care channels, overlapping BioLytical's HIV/STI portfolio and global distribution model.

TypeBroad incumbent
Description

bioMérieux is a major in vitro diagnostics company serving clinical and industrial microbiology markets, providing broader diagnostic instrument and reagent portfolios that overlap BioLytical's infectious disease focus at a much larger scale.

TypeBroad incumbent
Description

QuidelOrtho develops rapid immunoassay and molecular diagnostic products (Sofia, Triage) sold to hospitals, physician offices, and retail — overlapping BioLytical's rapid-test positioning in infectious disease screening with greater commercial scale.

TypeBroad incumbent
Description

Hologic's diagnostics division sells HIV, STI, and women's health assays including the Aptima and Panther molecular platforms — overlapping BioLytical's HIV/STI focus from a higher-accuracy, centralized-lab angle while competing for the same clinical budgets.

TypeBroad incumbent
Description

Cepheid's GeneXpert system delivers molecular HIV, HCV, and HBV viral load testing in decentralized settings — competing for global health and public health program budgets that also purchase BioLytical's rapid antibody tests.

TypeEmerging player
Description

Atomo is an Australian rapid diagnostics company focused on integrated HIV and HCV self-test devices — a smaller emerging peer with overlapping point-of-care HIV testing technology and emerging-market distribution ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioLytical Laboratories

In-Vitro Rapid Diagnosticsbiolytical.com

BioLytical Laboratories is a Canadian rapid diagnostics company that develops and manufactures one-minute INSTI and 15-minute iStatis point-of-care tests for HIV, HCV, syphilis, hepatitis B, and COVID-19, distributed in over 70 countries via channel partners, pharmacies, and public health programs.

What BioLytical Laboratories does

BioLytical Laboratories Inc. is a privately held Canadian biotechnology company headquartered in Richmond, British Columbia, with a U.S. operating office in Ferndale, Washington. Founded in 2005, the company develops and manufactures rapid point-of-care diagnostic tests built around a proprietary flow-through immunoassay platform that delivers results in as little as one minute. Its product portfolio is organized under two sub-brands: INSTI (one-minute tests for HIV self-test, HIV-1/2 antibody, multiplex HIV/Syphilis, and HCV antibody) and iStatis (15-minute tests for COVID-19 antigen, syphilis antibody, and hepatitis B surface antigen).

The company derives revenue primarily through the sale of hardware diagnostic kits to a diversified mix of channel partners, including regional and international distributors, pharmacy networks, group purchasing organizations such as Vizient, and government/NGO-led public health programs including Together TakeMeHome and Coalition Plus. Pricing is not publicly disclosed and is negotiated through dedicated account managers. BioLytical has secured multi-jurisdictional regulatory approvals (FDA, Health Canada, WHO Prequalification, CE Mark, Australian ARTG) and distributes in 70+ countries, with more than 35 million people tested cumulatively using its products.

BioLytical's go-to-market combines channel-partner distribution with event-driven demand generation at major healthcare conferences (Medica, Arab Health, USCHA, IAS, EACS) and a direct-to-consumer motion for the INSTI HIV Self Test via pharmacies and U.S. public health programs. Its competitive position rests on test speed (the world's fastest HIV test), integrated control features, room-temperature stability eliminating cold chain requirements, and a regulatory footprint spanning 70+ jurisdictions.

BioLytical Laboratories firmographics

Firmographics
Name
BioLytical Laboratories
Legal name
bioLytical Laboratories Inc.
Website
https://biolytical.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
BioLytical Laboratories is a Canadian rapid diagnostics company that develops and manufactures one-minute INSTI and 15-minute iStatis point-of-care tests for HIV, HCV, syphilis, hepatitis B, and COVID-19, distributed in over 70 countries via channel partners, pharmacies, and public health programs.
Ownership category
akta.pro rank

BioLytical Laboratories industry classification

Industry
Product category
In-Vitro Rapid Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Rapid diagnostic tests
  • Point-of-care testing
  • HIV self-testing
  • Flow-through immunoassay
  • Infectious disease diagnostics

Where BioLytical Laboratories is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

BioLytical Laboratories business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Rapid Diagnostic Test Kits: Sale of INSTI and iStatis rapid test products for HIV, HCV, Syphilis, COVID-19, and Hepatitis B. Products are sold to healthcare providers, distributors, pharmacies, and directly to consumers. Manufacturing with short lead times and fast shipping.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

BioLytical Laboratories product offering

Product offering

Core offering

BioLytical Laboratories develops and manufactures rapid point-of-care diagnostic test kits under the INSTI (1-minute tests) and iStatis (15-minute tests) brands for HIV, HCV, Syphilis, COVID-19, and Hepatitis B. The company sells both professional-use tests to healthcare providers and self-tests directly to consumers, using proprietary flow-through immunoassay technology that delivers results without timing devices, refrigeration, or specialized equipment. Products are distributed globally across 70+ countries through distributor networks, pharmacy chains, and group purchasing organizations.

Product overview

BioLytical Laboratories offers a portfolio of rapid point-of-care diagnostic tests organized under two sub-brands: INSTI (1-minute tests) and iStatis (15-minute tests). The INSTI line includes HIV self-test, HIV-1/2 antibody test, multiplex HIV/syphilis test, and HCV antibody test. The iStatis line includes COVID-19 antigen tests (home and professional), syphilis antibody test, and hepatitis B surface antigen test. The company utilizes proprietary flow-through immunoassay technology that enables near-instant results without the need for timing devices, refrigeration, or complex procedures. Tests are designed for both self-use (consumer) and professional point-of-care settings, supporting disease screening in over 70 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • INSTI: Premium rapid test brand featuring the world's fastest HIV test with results in 1 minute, includes HIV Self Test, HIV-1 HIV-2 Antibody Test, Multiplex HIV-1/2 Syphilis Test, and HCV Antibody Test.
  • iStatis

Products and services

  • INSTI HIV Self Test A rapid, single-use, visual-read self-test that detects antibodies against HIV type 1 and type 2 using a drop of blood from a finger prick. Provides results in 60 seconds with 99.8% sensitivity and 99.5% specificity. Designed for personal at-home use by individual consumers.
  • INSTI HIV-1 HIV-2 Antibody Test A rapid, single-use, visual-read flow-through immunoassay for professional use that detects antibodies against HIV-1 and HIV-2 using capillary whole blood, venous whole blood, serum, or plasma samples. Delivers results in 1 minute and is used by healthcare professionals in clinical settings.
  • INSTI Multiplex HIV-1/2 Syphilis Antibody Test A rapid multiplex test that detects antibodies to both HIV-1/2 and syphilis from a single sample, providing two results in one minute. Designed for point-of-care professional use in clinical settings.
  • INSTI HCV Antibody Test The world's first CE-marked 1-minute hepatitis C antibody rapid test, enabling detection of HCV antibodies to help eliminate HCV as a public health problem. For professional use.
  • iStatis COVID-19 Antigen Home Test A rapid antigen home test for detecting active COVID-19 infection, providing results in 15 minutes. Received WHO Prequalification for global market access and is designed for personal use at home.
  • iStatis COVID-19 Antigen Test A professional-use rapid antigen test for detecting active COVID-19 infection, delivering results in 15 minutes. Authorized by Health Canada for identifying active infections in clinical settings.
  • iStatis Syphilis Antibody Test A rapid point-of-care test for detecting syphilis antibodies, providing results in under 15 minutes. Included in the Australian Register of Therapeutic Goods (ARTG) for distribution in Australia. For professional use.
  • iStatis Hepatitis B Surface Antigen Test North America's first Health Canada-authorized rapid point-of-care test for hepatitis B, providing results in 15 minutes. Designed to improve access to hepatitis B screening and early diagnosis. For professional use.

Quantifiable outcome

  • >99% sensitivity (Positive Percent Agreement) and >99% specificity (Negative Percent Agreement) for INSTI HIV tests
  • +3 more outcomes

Companies that use BioLytical Laboratories

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

BioLytical Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioLytical Laboratories partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, minor and regional.

  • WalgreenscoreChannel Partner/ Reseller/ Distributor · 23 June 2026Walgreens serves as a distribution partner for bioLytical's INSTI HIV Self Tests. bioLytical donated 4,200 INSTI HIV Self Tests for National HIV Testing Day activities at Walgreens locations across the USA, marking the company's first donation of self-tests within the US market.
  • Together TakeMeHomecoreStrategic or Co-development PartnerPartnership to support Together TakeMeHome's national program delivering free HIV self-tests directly to individuals across the United States. bioLytical's INSTI HIV Self Test is included in this free testing initiative.
  • VizientcoreChannel Partner/ Reseller/ DistributorVizient awarded an innovative technology contract to bioLytical for the INSTI rapid HIV test. This contract enables healthcare facilities within the Vizient network to access INSTI testing products.
  • Coalition PlusminorStrategic or Co-development PartnerPartnership with international NGO Coalition Plus to donate HIV tests supporting International Testing Week initiatives aimed at increasing global testing access.
  • Kenya Pharmacy NetworksregionalChannel Partner/ Reseller/ DistributorINSTI HIV Self Test launched through Kenya's regulated pharmacy network, enabling wider access to HIV self-testing across Kenya.
  • WHO-UNITAIDcoreStrategic or Co-development PartnerActive participation in WHO-UNITAID Manufacturers events to support global access to affordable diagnostic testing.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

BioLytical Laboratories competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: OraSure is the most direct peer, selling the OraQuick HIV self-test and other rapid infectious disease diagnostics with similar point-of-care positioning, OTC approvals, and global health distribution — directly competing with INSTI on HIV self-testing.
  • Chembio Diagnostics: Chembio develops rapid point-of-care immunoassay tests for HIV, syphilis, and febrile illness with comparable technology, regulatory pathway (FDA, WHO Prequalification), and target customer base of NGOs and public health programs.
  • SD Biosensor: SD Biosensor is a Korean rapid diagnostics maker with HIV, COVID, and infectious disease lateral-flow products sold globally, including strong presence in emerging markets and WHO Prequalified assays — directly competing with both INSTI and iStatis.
  • Trinity Biotech: Trinity Biotech manufactures diagnostic tests for HIV, hepatitis, and other infectious diseases sold through clinical labs and point-of-care channels, overlapping BioLytical's HIV/STI portfolio and global distribution model.

Broad incumbents

  • Abbott Diagnostics (Alere): Abbott is a global diagnostics incumbent whose rapid test portfolio (BinaxNOW, Determine, m-PIMA) competes across HIV, hepatitis, and infectious disease markets with much greater scale, distribution reach, and hospital contracts than BioLytical.
  • bioMérieux: bioMérieux is a major in vitro diagnostics company serving clinical and industrial microbiology markets, providing broader diagnostic instrument and reagent portfolios that overlap BioLytical's infectious disease focus at a much larger scale.
  • QuidelOrtho: QuidelOrtho develops rapid immunoassay and molecular diagnostic products (Sofia, Triage) sold to hospitals, physician offices, and retail — overlapping BioLytical's rapid-test positioning in infectious disease screening with greater commercial scale.
  • Hologic: Hologic's diagnostics division sells HIV, STI, and women's health assays including the Aptima and Panther molecular platforms — overlapping BioLytical's HIV/STI focus from a higher-accuracy, centralized-lab angle while competing for the same clinical budgets.
  • Cepheid (Danaher): Cepheid's GeneXpert system delivers molecular HIV, HCV, and HBV viral load testing in decentralized settings — competing for global health and public health program budgets that also purchase BioLytical's rapid antibody tests.

Emerging players

  • Atomo Diagnostics: Atomo is an Australian rapid diagnostics company focused on integrated HIV and HCV self-test devices — a smaller emerging peer with overlapping point-of-care HIV testing technology and emerging-market distribution ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

BioLytical Laboratories social profiles

Digital presence

BioLytical Laboratories compliance and trust

Trust signal

Compliance6 records

BioLytical Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioLytical Laboratories leadership team

Management profile

Number of profiles

Profiles4 records

BioLytical Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioLytical Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLytical Laboratories

What does BioLytical Laboratories do?

BioLytical Laboratories develops and manufactures rapid point-of-care diagnostic test kits under the INSTI (1-minute tests) and iStatis (15-minute tests) brands for HIV, HCV, Syphilis, COVID-19, and Hepatitis B. The company sells both professional-use tests to healthcare providers and self-tests directly to consumers, using proprietary flow-through immunoassay technology that delivers results without timing devices, refrigeration, or specialized equipment. Products are distributed globally across 70+ countries through distributor networks, pharmacy chains, and group purchasing organizations.

Is BioLytical Laboratories a public or private company?

BioLytical Laboratories is a private company. It is classified as management employee owned and is currently operating.

When was BioLytical Laboratories founded?

BioLytical Laboratories was founded in 2005. It employs 101 to 250 people.

Where is BioLytical Laboratories based?

BioLytical Laboratories is headquartered in Richmond, Canada, in the North America region.

How does BioLytical Laboratories make money?

One revenue line is on record: rapid Diagnostic Test Kits.

Who are BioLytical Laboratories's main competitors?

Direct peers on record are OraSure Technologies, Chembio Diagnostics, SD Biosensor and Trinity Biotech. Broad incumbents are Abbott Diagnostics (Alere), bioMérieux, QuidelOrtho, Hologic and Cepheid (Danaher). Atomo Diagnostics is listed as an emerging player.

Does BioLytical Laboratories have an API?

No public API is recorded for BioLytical Laboratories.

What industry is BioLytical Laboratories in?

BioLytical Laboratories's product category is In-Vitro Rapid Diagnostics. Its primary akta.pro industry code is HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories, with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceThousands of Free HIV Tests to Support National HIV Testing Day Activities Across the United StatesbioLytical Laboratories is donating 4,200 INSTI HIV self tests to Walgreens for National HIV Testing Day activities at over 350 U.S. locations. This marks the company's first donation of INSTI self tests to the initiative, with results in 60 seconds or less. The tests are also available through Amazon and public health programs.GlobeNewswireThousands of Free HIV Tests to Support National HIV Testing Day Activities Across the United StatesbioLytical donated INSTI HIV self-tests to support National HIV Testing Day activities at over 350 Walgreens locations. This is the company's first donation of self-tests to the initiative, which is observed on June 27. The self-tests are also available through Amazon and public health programs.GlobeNewswireHealth Canada Authorizes North America’s First Hepatitis B Rapid Test, bioLytical’s iStatis Hepatitis B Surface Antigen TestHealth Canada authorized bioLytical's iStatis Hepatitis B Surface Antigen test, the first rapid point-of-care test for hepatitis B in North America. The test delivers results in 15 minutes and is designed for clinics, mobile units, and community settings. It supports Canada's public health goals to eliminate viral hepatitis by 2030.GlobeNewswireWorld’s Fastest HIV Test added to the Together TakeMeHome Program for Free at Home HIV Self-Testing Across the United StatesbioLytical Laboratories announced a partnership with the Together TakeMeHome program to distribute INSTI HIV self-tests via mail to U.S. residents. The INSTI test provides results in 60 seconds or less, and the program is CDC-funded. The collaboration aims to expand access to rapid HIV self-testing across the United States.GlobeNewswireHIV Self-Testing Just Got Faster: FDA Approves the 1-Minute INSTI® HIV Self TestThe U.S. Food and Drug Administration has approved bioLytical Laboratories Inc.'s INSTI® HIV Self Test, making it the first one-minute HIV self-test available in the U.S. market. The test delivers highly accurate results using a single drop of blood and is designed to expand access to HIV screening by enabling private, at-home testing without clinic appointments. The approval supports the U.S. public health goal of reducing HIV infections by 90% by 2030 under the Ending the HIV Epidemic initiative.GlobeNewswirebioLytical’s iStatis Syphilis Antibody Test Now Included in the Australian Register of Therapeutic Goods (ARTG)bioLytical Laboratories Inc. announced that its iStatis Syphilis Antibody Test has been included in the Australian Register of Therapeutic Goods, allowing distribution across Australia. The test provides rapid, accurate results within 15 minutes and supports efforts to reduce syphilis transmission in the country.GlobeNewswirebioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in CanadabioLytical Laboratories received Health Canada authorization for its INSTI HCV Antibody Test for professional use in Canada, allowing immediate market entry. The test offers 97.15% sensitivity and 99.47% specificity, with results in one minute or less. The company will manufacture and distribute the test in Richmond, B.C.GlobeNewswirebioLytical Announces Final Results of Substantial Issuer BidbioLytical Laboratories paid CAD$2,735,200.05 for 18,234,667 common shares under its substantial issuer bid, representing about 6.20% of shares outstanding. Payment will be completed by Odyssey Trust Company.Business InsiderbioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in AustraliabioLytical Laboratories announced the immediate availability of its INSTI HCV antibody test in Australia, the first point-of-care rapid test for hepatitis C antibody detection in the country. The test, with ARTG number 448926, provides results in one minute and is manufactured in Canada for Australian distribution. The company aims to help meet Australia's 2030 hepatitis C elimination target.